Background & aims: Very few data are available in literature about the role of radiofrequency ablation (RFA) in intrahepatic cholangiocarcinoma (ICC) and previous studies are mainly case reports and case series on a very small number of patients and nodules. In this study, we aimed to evaluate effectiveness and safety of RFA for the treatment of unresectable ICC. Methods: This is a retrospective observational cohort study comprising all consecutive patients treated with RFA for unresectable ICC at Policlinico Sant'Orsola Malpighi Hospital, Bologna, Italy. Primary endpoint was Local Tumor Progression-Free Survival (LTPFS) while Overall Survival (OS) was also assessed as secondary endpoint. Results: From January 2014 to June 2019, 29 patients with 117 nodules underwent RFA. Technique effectiveness 1 month after RFA was 92.3%; median LTPFS was 9.27 months. Univariate analysis and multivariate analysis showed that LTPFS was significantly related to tumor size ≥20 mm. At a median follow up of 39.9 months, median OS from the date of RFA was 27.5 months, with an OS of 89%, 45% and 11% at 1, 2 and 4 years, respectively. Number of overall lesions and the sum of their diameter at the moment of the first RFA significantly affected OS in multivariate analysis. Minor and major complication rates were 14% and 7%, respectively. Conclusion: Tumor size ≥20 mm was associated with lower LTPFS, representing a potential useful threshold value. A careful evaluation of tumor burden appears as a crucial element in choosing the best therapeutic strategy in unresectable ICC.
Background & aims: Very few data are available in literature about the role of radiofrequency ablation (RFA) in intrahepatic cholangiocarcinoma (ICC) and previous studies are mainly case reports and case series on a very small number of patients and nodules. In this study, we aimed to evaluate effectiveness and safety of RFA for the treatment of unresectable ICC. Methods: This is a retrospective observational cohort study comprising all consecutive patients treated with RFA for unresectable ICC at Policlinico Sant'Orsola Malpighi Hospital, Bologna, Italy. Primary endpoint was Local Tumor Progression-Free Survival (LTPFS) while Overall Survival (OS) was also assessed as secondary endpoint. Results: From January 2014 to June 2019, 29 patients with 117 nodules underwent RFA. Technique effectiveness 1 month after RFA was 92.3%; median LTPFS was 9.27 months. Univariate analysis and multivariate analysis showed that LTPFS was significantly related to tumor size ≥20 mm. At a median follow up of 39.9 months, median OS from the date of RFA was 27.5 months, with an OS of 89%, 45% and 11% at 1, 2 and 4 years, respectively. Number of overall lesions and the sum of their diameter at the moment of the first RFA significantly affected OS in multivariate analysis. Minor and major complication rates were 14% and 7%, respectively. Conclusion:Tumor size ≥20 mm was associated with lower LTPFS, representing a potential useful threshold value. A careful evaluation of tumor burden appears as a crucial element in choosing the best therapeutic strategy in unresectable ICC.
Authors: Angela Dalia Ricci; Alessandro Rizzo; Chiara Bonucci; Simona Tavolari; Andrea Palloni; Giorgio Frega; Veronica Mollica; Nastassja Tober; Elena Mazzotta; Cristina Felicani; Carla Serra; Giovanni Brandi Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Tao Wang; Jinfu Zhang; Wanxiang Wang; Xianwei Yang; Junjie Kong; Shu Shen; Wentao Wang Journal: Cancer Manag Res Date: 2020-11-02 Impact factor: 3.989
Authors: Maria A Gonzalez-Carmona; Christian Möhring; Robert Mahn; Taotao Zhou; Alexandra Bartels; Farsaneh Sadeghlar; Maximilian Bolch; Annabelle Vogt; Dominik J Kaczmarek; Dominik J Heling; Leona Dold; Jacob Nattermann; Vittorio Branchi; Hanno Matthaei; Steffen Manekeller; Jörg C Kalff; Christian P Strassburg; Raphael U Mohr; Tobias J Weismüller Journal: Sci Rep Date: 2022-01-19 Impact factor: 4.379
Authors: Alessandro Rizzo; Alessandro Di Federico; Angela Dalia Ricci; Giorgio Frega; Andrea Palloni; Rachele Pagani; Simona Tavolari; Mariacristina Di Marco; Giovanni Brandi Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302